Skip to content

Preventing Medication-Related Problems in Care Transitions to Skilled Nursing Facilities

Preventing Medication-Related Problems in Care Transitions to Skilled Nursing Facilities Using a Pharmacy Integrated Transitional Team

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05241951
Enrollment
1052
Registered
2022-02-16
Start date
2022-01-31
Completion date
2025-10-31
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Care Transition

Keywords

Care Transition, Medication-Related Problems, Post-Acute Care, Skilled Nursing Facility, Hospital Systems, Medication Safety

Brief summary

The Pharmacy Integrated Transitions (PIT) program, utilizes a crossover randomized control design to evaluate the impact of a clinical pharmacist in decreasing medication related problems during a patient's transition from hospital to skilled nursing facility (SNF).

Detailed description

Standard hospital discharge processes (e.g. as recommended by the Joint Commission Center for Transforming Healthcare), include hospital staff completing a paper-based discharge summary and medication reconciliation form. To reduce the likelihood of medication-related problems during care transitions, the Pharmacy Integrated Transitions (PIT) program aims to improve the standard transition process by adding a coordinating transitional pharmacist to provide a structured synchronous warm-handoff between clinical teams at the hospital and the Skilled Nursing Facility, in addition to reconciling, adjusting, and monitoring medications during and after discharge from the hospital.

Interventions

OTHERStructured hand-off

Use of standardized checklist to provide synchronous or asynchronous handoff that conveys medication recommendations to the SNF clinical teams

OTHERMedication reconciliation during transitional period

Comprehensive medication reconciliation conducted during transitional period between hospital and SNF, focused on SNF-specific requirements for medication delivery (e.g., stop dates, titration instructions)

OTHERTransitional medication monitoring

Review of medication orders during first 7 days of SNF admittance to address barriers to translation of medication orders and appropriate medication delivery

OTHERTeleconsultation

Ad hoc consultation to provide additional clarification to SNF clinical teams

Sponsors

Agency for Healthcare Research and Quality (AHRQ)
CollaboratorFED
University of Washington
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Intervention model description

A parallel cluster-randomized controlled crossover trial design, with randomization occurring at the skilled nursing facility cluster level. The trial is conducted across four hospitals and 14 independent SNFs in Washington State. SNF's are stratified by patient volume before randomly assigned to either the PIT program or usual care.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18 years of age and older * patients receiving inpatient care at University of Washington Mountlake, University of Washington Northwest, Harborview, and Valley Medical Center hospitals to one of 14 collaborating SNF's on a day when the PIT program pharmacist is conducting the intervention

Exclusion criteria

* Under 18 years of age * patients with a discharge on hospice care * patients discharged on days that the pharmacist is not conducting the intervention

Design outcomes

Primary

MeasureTime frameDescription
Medication Related Problems30 days post hospital dischargeNumber of medication related problems experienced by patients within 30 days post hospital discharge.

Secondary

MeasureTime frameDescription
Death30 Days post hospital dischargeNumber of deaths experienced by patients within each cohort
Readmissions30 DaysNumber of readmissions within 30 days of index hospital discharge

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026